Copeptin and HFABP in Cardiac Surgery
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · May 6, 2021
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
The initial patient visit will take place after screening of patients and eligibility assessment and no later than on the day before surgery (day -1). After provision of patient information and written informed consent, baseline data will be extracted from clinical source documents. Blood will be sampled prior to induction (Troponin), upon arrival in the intensive care unit (Troponin, HFABP and Copeptin), and on postoperative day 1 and 2 (Troponin). Sampling will occur as far as possible concurrently to clinically indicated blood samples. Blood samples will be analyzed in a certified labora...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥ 18 years of age)
- • Elective surgery
- • On-pump cardiac surgery (CABG and/or valvular surgery)
- Exclusion Criteria:
- • Heart transplantation (HTX)
- • ACS at presentation (\< 14 days)
- • Emergency surgery
- • Preoperative inotropic or mechanical circulatory support
- • Left or right ventricular assist device implantation
- • Unwilling or unable to provide consent
- • Inability to follow the procedures of the study, e.g. due to language barriers, psychiatric disorders, dementia
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Düsseldorf, Nrw, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials